|

Anti-GARP Chimeric Antigen Receptor-T Cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anti-GARP CAR T Cells (SY), Anti-GARP CAR T-cells (SY), Anti-GARP CAR-T Cells (SY)

Pipeline

Phase 1: 1

Top Sponsors

  • Ohio State University Comprehensive Cancer Center1

Indications

  • WHO Grade 3 Glioma1
  • WHO Grade 2 Glioma1
  • Recurrent WHO Grade 4 Glioma1
  • Recurrent WHO Grade 3 Glioma1
  • Recurrent Malignant Glioma1

Columbus, Ohio1 trial

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.